Business & Industry News Channel

Novartis Foundation symposium showcases sustainable healthcare interventions

NovartisToday, the Novartis Foundation, formerly named the Novartis Foundation for Sustainable Development, convenes its annual symposium. This year's topic - "Sustainable healthcare interventions: from blueprint to lasting impact" - brings together philanthropists, local partners and innovators to explore the journey from idea generation and pilot projects to the realization of scalable and sustainable healthcare systems that improve outcomes for patients in low- and middle-income countries.


Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

Boehringer IngelheimTwo new real-world data analyses presented at the American Heart Association's Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin.(1,2)


Novo Nordisk second best in the world at providing access to medicine

Novo NordiskToday, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities.


Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Ireland

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) today announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company's growing biologics portfolio.


AstraZeneca announces initiation of development programme for BRILINTA® reversal agent

AstraZenecaAstraZeneca today announced that it has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA®) in rare emergency situations such as urgent surgery, or in the event of major bleeding.


Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China. The new manufacturing site sets out to address the continuously growing demand for diagnostic tests in China and the Asia Pacific region.


Bayer operationally strong - strategic focus on Life Science businesses

BayerSales of the Bayer Group rose by 5.6 percent in the third quarter of 2014 to EUR 10,187 million (Q3 2013: EUR 9,643 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales grew by 7.4 percent. EBIT rose by 12.7 percent to EUR 1,376 million (Q3 2013: EUR 1,221 million).


World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]